uniQure N.V. $QURE Stake Cut by Aberdeen Group plc

Aberdeen Group plc cut its stake in uniQure N.V. (NASDAQ:QURE – Free Report) by 99.5% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 13,425 shares of the biotechnology company’s stock after selling 2,834,692 shares during the quarter. Aberdeen Group plc’s holdings in uniQure were worth $324,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Orbimed Advisors LLC increased its holdings in shares of uniQure by 189.7% during the 1st quarter. Orbimed Advisors LLC now owns 2,136,149 shares of the biotechnology company’s stock worth $34,926,000 after buying an additional 1,398,749 shares during the last quarter. Two Seas Capital LP acquired a new stake in uniQure during the third quarter worth $31,988,000. Assenagon Asset Management S.A. increased its position in shares of uniQure by 249.9% during the 2nd quarter. Assenagon Asset Management S.A. now owns 513,530 shares of the biotechnology company’s stock worth $23,653,000 after purchasing an additional 366,781 shares during the last quarter. Maverick Capital Ltd. raised its holdings in uniQure by 5.4% in the 1st quarter. Maverick Capital Ltd. now owns 697,640 shares of the biotechnology company’s stock valued at $11,406,000 after buying an additional 35,820 shares during the period. Finally, Readystate Asset Management LP raised its holdings in uniQure by 39.6% in the 1st quarter. Readystate Asset Management LP now owns 504,702 shares of the biotechnology company’s stock valued at $8,252,000 after buying an additional 143,142 shares during the period. 78.83% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the stock. HC Wainwright lowered their price objective on shares of uniQure from $80.00 to $65.00 and set a “buy” rating for the company in a research report on Wednesday. Barclays downgraded shares of uniQure from an “overweight” rating to an “equal weight” rating and dropped their target price for the company from $60.00 to $28.00 in a report on Monday, October 5th. Royal Bank Of Canada cut their target price on uniQure from $65.00 to $48.00 and set an “outperform” rating on the stock in a research report on Friday, October 2nd. Wolfe Research raised uniQure from a “peer perform” rating to an “outperform” rating and set a $65.00 target price on the stock in a research report on Wednesday, July 29th. Finally, Wall Street Zen upgraded uniQure from a “sell” rating to a “hold” rating in a research note on Saturday, November 7th. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $55.58.

Check Out Our Latest Stock Analysis on uniQure

Latest uniQure News

These are some of the QURE news items that stood out recently:

  • Positive Sentiment: HC Wainwright raised its estimates for FY2026 and FY2027, as well as several quarterly forecasts, indicating smaller expected losses. The firm kept its Buy rating. Analyst estimate details
  • Neutral Sentiment: Analyst coverage cited an average price target of $56.83, though that figure alone does not indicate a new change in sentiment. Average price target report
  • Negative Sentiment: HC Wainwright cut its price target to $65 and lowered its FY2029 and FY2030 earnings estimates, tempering the more favorable near-term revisions. It nevertheless retained its Buy rating. Price target report Target cut coverage

uniQure Stock Performance

Shares of uniQure stock opened at $19.35 on Friday. The firm has a market capitalization of $1.36 billion, a P/E ratio of -5.51 and a beta of 1.14. uniQure N.V. has a 52 week low of $8.73 and a 52 week high of $51.72. The company has a quick ratio of 11.52, a current ratio of 11.52 and a debt-to-equity ratio of 0.17. The firm’s 50 day moving average is $27.05 and its two-hundred day moving average is $29.58.

uniQure (NASDAQ:QURE – Get Free Report) last released its quarterly earnings data on Wednesday, November 4th. The biotechnology company reported ($0.88) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.04. The company had revenue of $5.20 million for the quarter, compared to analysts’ expectations of $6.17 million. uniQure had a negative net margin of 1,154.84% and a negative return on equity of 96.34%. Research analysts forecast that uniQure N.V. will post -3.79 EPS for the current fiscal year.

About uniQure

(Free Report)

uniQure N.V. is a biotechnology company that develops gene therapies for serious genetic and other diseases. The company uses adeno-associated virus (AAV) vectors to deliver genetic material to patients’ cells, with research and development operations in the United States and the Netherlands. Its programs have targeted conditions including Huntington’s disease, epilepsy and hemophilia B. uniQure developed the gene therapy now known as Hemgenix for hemophilia B; it is commercialized by CSL Behring under a partnership.

Featured Articles

Want to see what other hedge funds are holding QURE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for uniQure N.V. (NASDAQ:QURE – Free Report).

Institutional Ownership by Quarter for uniQure (NASDAQ:QURE)

Receive News & Ratings for uniQure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure and related companies with MarketBeat.com's FREE daily email newsletter.